Lipum offer a new route for treatment of chronic inflammatory diseases. Meet with our CEO Einar Pontén and our CMC Project Manager Mats Reslow at BIO-Europe 2018 in Copenhagen, Nov 5-7. We will tell you more on our novel target Bile Salt-Stimulated Lipase (BSSL) and our ongoing development of a therapeutic antibody for treatment of these diseases.
Lipum has collected original research data proving the efficacy of the compound in several established arthritis models. The BSSL antibodies effectively block human inflammatory cell migration. We have selected candidate drug that is a monoclonal antibody that target BSSL. We are now heading for verifying pre-clinical studies, toxicological tests and clinical trials. Lipum is actively seeking partners for a faster development, read more here